Skip to Main Content

Paper Details

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Blood
10
2023
AML, AML blasts, Acute myeloid leukemia, CD123, CD3, CD33, CD371, FLZ, HCT, IFN-, JAK, MHC, MHC class II, MHC-II, STAT, T, THP-1 AML cell line, acute myeloid leukemia, acute myeloid leukemia cells, chimeric, chimeric antigen receptor expressing T cells, flotetuzumab, graft-versus-malignancy, interferon gamma, major histocompatibility class II, patient-derived xenograft model, patients, primary AML samples
Author NameAffiliation
Reyka G JayasingheWashington University School of Medicine
Reyka G JayasingheWashington University School of Medicine
Matthew J ChristopherWashington University School of Medicine
John F DiPersioWashington University School of Medicine
  • 1 - 4

Datasets

Release 1.2